Cavinton ampoules 0.5% 10ml №5

Indications and usage

Reducing the severity of neurological and mental symptoms in various forms of circulatory insufficiency of the brain:
- ischemic stroke.
- The recovery stage of hemorrhagic stroke.
- Consequences of a stroke.
- Transient ischemic attack.
- Vascular dementia.
- Vertebrobasilar insufficiency.
- Atherosclerosis of cerebral vessels.
- Post-traumatic and hypertensive encephalopathy.
- Thrombosis / occlusion / central artery or vein of the retina.
- Perceptual-type hearing loss.
- Diseases of Meniere.
- Idiopathic tinnitus.

Contraindications

- Acute phase of hemorrhagic stroke.
- Severe form of CHD.
- Severe arrhythmias.
- Pregnancy.
- Lactation period.
- Age up to 18 years (due to insufficient data).
- Known hypersensitivity to Vinpocetine.

Pregnancy and Breastfeeding

Cavinton is contraindicated for use in pregnancy. Data on the safety of Cavinton during lactation (breastfeeding) are not available.

Dosage and administration

The drug is intended for intravenous drip infusion. Inject slowly, the infusion rate should not exceed 80 drops / min. It is forbidden to enter in / m and / in without dilution.

To prepare the infusion, you can use saline or solutions containing dextrose (Salsol, Ringer, Index, Reomacrodex). Infusion solution with Cavinton should be used in the first 3 hours after preparation.

The usual initial daily dose is 20-25 mg per 500 ml of infusion solution. Depending on tolerance, within 2-3 days the dose can be increased to no more than 1 mg / kg / day. The average duration of treatment is 10-14 days. The average daily dose with a body weight of 70 kg - 50 mg (in 500 ml of infusion solution).

In diseases of the liver and kidneys, dose adjustment is not required.

Adverse reactions

Side effects against the use of the drug were rarely detected.

Cardiovascular: ECG change (ST depression, prolongation of the QT interval), tachycardia, extrasystole (causal relationship with taking the drug has not been proven, because in the natural population these symptoms are observed with the same frequency); change in blood pressure (often reduced), redness of the skin, phlebitis.

From the side of the central nervous system: sleep disorders (insomnia, increased drowsiness), dizziness, headache, general weakness (these symptoms may be manifestations of the underlying disease).

Gastrointestinal: dry mouth, nausea, heartburn.

Other: allergic skin reactions, increased sweating.

Special notes

The presence of prolonged QT syndrome and taking drugs that cause lengthening of the QT interval, requires periodic monitoring of the ECG.

Cavinton infusion solution contains sorbitol (160 mg / 2 ml), therefore, in the presence of diabetes, it is necessary to periodically monitor the level of glucose in the blood.

In the case of fructose intolerance or deficiency of fructose 1,6-diphosphatase, the use of vinpocetine should be avoided.

With simultaneous use is not observed interaction with beta-blockers (chloranolol, pindolol), clopamide, glibenclamide, Digoxin, acenocoumarol or hydrochlorothiazide.

In rare cases, simultaneous use with alpha-methyldopa is accompanied by a slight increase in the anti-hypertensive effect; when using such a combination, regular blood pressure control is necessary.

Despite the lack of data confirming the possibility of interaction, it is recommended that caution be exercised while simultaneously prescribing with drugs of the central nervous, anti-arrhythmic action.

Pharmaceutical interaction: Concentrate for preparation of the solution for infusions and Heparin are chemically incompatible, therefore it is prohibited to administer them in one infusion mixture, however, it is possible to simultaneously treat with anticoagulants and vinpocetine. Concentrate for solution for infusion is incompatible with infusion solutions containing amino acid, therefore they cannot be used for Cavinton dilution.

Overdosage

Symptoms: increased side effects.
Treatment: gastric lavage, reception of Activated carbon, symptomatic therapy.

Store in a dark place at a temperature of 15-30 ° C.

5 years.